Get the Stockscreener App
7.17
2.32%
-0.17
After Hours:
7.17
Tenax Therapeutics Inc stock is traded at $7.17, with a volume of 46,151.
It is down -2.32% in the last 24 hours and down -4.40% over the past month.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
See More
Previous Close:
$7.34
Open:
$7.45
24h Volume:
46,151
Relative Volume:
0.62
Market Cap:
$32.71M
Revenue:
-
Net Income/Loss:
$-14.56M
P/E Ratio:
-0.4263
EPS:
-16.82
Net Cash Flow:
$-12.46M
1W Performance:
-4.40%
1M Performance:
-4.40%
6M Performance:
+24.37%
1Y Performance:
+59.87%
1-Day Range:
$7.095
$7.45
1-Week Range:
$7.0001
$7.75
52-Week Range:
$4.4542
$8.2438
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
7.17 | 33.49M | 0 | -14.56M | -12.46M | -16.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | Piper Sandler | Overweight |
| Oct-24-24 | Initiated | Leerink Partners | Outperform |
| Oct-14-24 | Initiated | Guggenheim | Buy |
| Sep-30-24 | Initiated | William Blair | Outperform |
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-16-14 | Initiated | MLV & Co | Buy |
| Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
Why Tenax Therapeutics Inc. stock is a must watch in 2025Sell Signal & Community Consensus Trade Alerts - newser.com
How sentiment analysis helps forecast Tenax Therapeutics Inc.Portfolio Gains Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Forecasting Tenax Therapeutics Inc. price range with options dataQuarterly Market Review & Weekly Return Optimization Plans - newser.com
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - Investing News Network
Top chart patterns to watch in Tenax Therapeutics Inc.CEO Change & High Win Rate Trade Tips - newser.com
Why retail investors favor Tenax Therapeutics Inc. stockMarket Movement Recap & Smart Investment Allocation Tips - newser.com
Should you hold or exit Tenax Therapeutics Inc. nowTrade Analysis Report & Daily Oversold Bounce Ideas - newser.com
How Tenax Therapeutics Inc. stock compares to growth peersEarnings Beat & High Accuracy Swing Trade Signals - newser.com
Combining machine learning predictions for Tenax Therapeutics Inc.Fed Meeting & Real-Time Sentiment Analysis - newser.com
Is now a turning point for Tenax Therapeutics Inc.Earnings Recap Report & Technical Confirmation Trade Alerts - newser.com
Can trapped investors hope for a rebound in Tenax Therapeutics Inc.2025 Valuation Update & Long-Term Growth Stock Strategies - newser.com
Historical volatility pattern of Tenax Therapeutics Inc. visualizedJuly 2025 EndofMonth & Reliable Volume Spike Alerts - newser.com
Will Tenax Therapeutics Inc. stock recover after recent dropTrade Risk Assessment & High Win Rate Trade Alerts - newser.com
Understanding Tenax Therapeutics Inc.’s price movementQuarterly Trade Summary & Daily Entry Point Alerts - newser.com
Will Tenax Therapeutics Inc. stock benefit from infrastructure spendingJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Analyzing drawdowns of Tenax Therapeutics Inc. with statistical toolsJuly 2025 PreEarnings & Free Fast Entry Momentum Trade Alerts - newser.com
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):